In our laboratory, preliminary studies have indicated that recombinant bovine somatotropin ® (rbST) can stimulate protective immunity against coccidia infection. A floor pen trial on coccidia-seeded litter was run to further test its activity as an adjuvant during immunization of chicks with a live oocyst vaccine. Five hundred day-old male broiler strain chicks were randomly assigned to five experimental Treatments: 1, medicated controls; 2, unimmunized, not treated with rbST; 3, unimmunized, rbST-treated; 4, immunized, not treated with rbST; 5, immunized, rbST-treated. Each treatment consisted of four pens of 25 chicks each. At the end of the growout period (7 wk), the chicks in Treatment 1 (medicated controls) had the highest mean BW, but mean BW of chickens in Treatment 3 (rbST treatment only) were not significantly less. On the other hand, the mean weights of chicks in Treatments 4 (immunized only) and 5 (immunized plus rbST) were significantly reduced, and not different from those of the untreated chickens (Treatment 2). However, when challenged at 3 wk, the chicks in Treatment 5 had a mean combined total lesion score that was significantly lower than that from Treatment 3, indicating that they had developed a higher degree of specific immunity, but at the expense of weight gain. The results suggest that rbST has a potential for use as an adjuvant with live oocyst vaccination, but that the ratio between rbST dose and numbers of oocysts in the live vaccine needs to be carefully controlled.
INTRODUCTION
Chickens are capable of developing solid, speciesspecific immunity to Eimeria sp. after one or several exposures to infection (Rose and Wakelin, 1990) . This immunity can develop quickly with a large dose of infective oocysts, or more slowly, and with less pathological manifestations, upon continuous exposure to small infective doses (Parry et al., 1989) . This latter means is the basis for the development of commercial live vaccines, such as COCCIVAC ® and IMMUCOX ® , in which young chickens are given small numbers of oocysts of several Eimeria species. The oocysts shed onto the litter from these initial mild infections are recycled in the chicken two to three times (Fitz-Coy, 1991) , and, in slowly increasing numbers, providing gradual exposure to a wide range of antigens that eventually elicit broad protective immunity.
A problem with the use of live vaccines, although rare, is the inability to develop immunity to some field strains of coccidia that are not included in the vaccine, resulting in an infection "break". One possible strategy to overcome this problem would be to nonspecifically stimulate immune responses with an immunomodulator.
In several exploratory experiments (Allen et al., 1997) , subcutaneous injection of day-old chicks with recombinant bovine somatotropin ® (rbST) was found to be beneficial in reducing cecal lesion scores of unimmunized or IMMUCOX ® -immunized chicks that had been challenged 4 wk postimmunization with Eimeria tenella. These results suggested that rbST may be an appropriate adjuvant.
To investigate this possibility further, we have run a floor pen trial to test the interaction of rbST treatment and live oocyst immunization on the performance of chickens placed on coccidia-seeded litter, an environment simulating a commercial poultry house. To assess the effects of the various treatments on the development of immunity, some chicks were randomly selected from each treatment at 3 wk and again at the end of the growout period of 7 wk, and challenged with large doses of the species comprising the live oocyst vaccine. 
MATERIALS AND METHODS

Birds, Housing, and Feed
Five hundred day-old male broiler 1 chicks were randomly divided into 20 treatment groups of 25 chicks each. Each group was raised in a separate floor pen (2.79 m 2 ). The litter in each pen was used, but top-dressed with 3 in of new pine shavings. It was then seeded, using a hand sprayer, with 1 L of a suspension of Eimeria acervulina, E. tenella, and Eimeria maxima oocysts (5 × 10 6 , 1.5 × 10 6 , and 1 × 10 6 respectively), all of which had been shown to have partial sensitivity to salinomycin. Birds were provided ad libitum access to feed, and water was provided by automatic Mark II Plasson drinkers. Lighting was continuous. Chicks were fed broiler starter feed 2 from 1 d of age through 3 wk, and grower feed 3 from 3 to 7 wk of age. Medicated control chicks were given the same feeds supplemented with 66 ppm Biocox ® . 4 The temperature of the pens was maintained at approximately 30 C using heat lamps the first 3 wk, but without heating thereafter.
Parasites and Lesion Scores
The following field strains of coccidia, obtained from commercial poultry growers, were used throughout this experiment for seeding the litter, for incorporation into a live vaccine, and for challenge infections: E. acervulina AC-72, 5 E. tenella, AC-34, 6 and E. maxima, M-3. 7 Lesions in the upper small intestine (SI) attributable to E. acervulina, the mid SI, attributable to E. maxima, and ceca, attributable to E. tenella were scored in a blinded manner on a scale from 0 through 4 according to Johnson and Reid (1970) . Total lesion scores were the sum of scores from the various intestinal segments.
Live Oocyst Vaccine
The vaccine was prepared as a gel (Danforth et al., 1996) containing viable oocysts of E. acervulina, E. tenella, and E. maxima. Chicks that were designated to be treated with the live vaccine were placed, at the hatchery, in transport boxes to which the gel was added. The chicks completely consumed the gel in transit from the hatchery to the floor pens. It was calculated that each vaccinated chick ingested about 1,000 oocysts of E. acervulina, 200 oocysts of E. maxima, and 300 oocysts of E. tenella.
Recombinant Bovine Somatotropin ®
The rbST was provided by Monsanto Company. 8 It was diluted to a concentration of 0.9 mg/mL with sterile water for injection 9 just prior to use. At the hatchery, each treated chick was injected subcutaneously at the nape of the neck with 0.1 mL of this solution. This procedure resulted in no apparent swelling or inflammation at the injection site.
Experimental Protocol
The experiment compared five treatments, each consisting, at the start, of four pens of 25 chicks each: 1) unimmunized, not treated with rbST, medicated (Biocox) controls, 2) unimmunized, not treated with rbST, 3) unimmunized, rbST-treated, 4) immunized, not treated with rbST, and 5) immunized, rbST-treated. Treatments per pen were arranged randomly throughout a single house. The experiment consisted of three parts: a growout lasting 7 wk with an assessment of weight gains and lesions at 3 wk, a challenge infection at 3 wk, and a challenge infection at 7 wk.
Growout. Group weights were obtained at 1 d of age and again at 3 wk of age [3 wk postimmunization (PI)]. At 3 wk of age, five chicks per pen were randomly selected, weighed, bled, and killed, and lesions in the upper-and mid-SI and ceca scored. An additional five chicks per pen were randomly selected for a challenge infection. The remaining (12 to 15) chicks per pen were weighed as groups at 3 and 7 wk in order to compare effects of treatments on total weight gains and feed conversions during the starter and grower periods.
Challenge at 3 wk. The randomly selected chicks were placed in four battery cages per treatment, five chicks per cage, given unmedicated grower feed, and each challenged by gavage (1 mL) with a mixture of 40,000 oocysts of E. acervulina, 10,000 oocysts of E. tenella, and 10,000 oocysts of E. maxima. They were assayed at 6 d postchallenge (PC) for weight gain, feed conversion, and lesions in upper-and mid-SI, and ceca. Weight gains were compared with those of five randomly selected unchallenged chicks per pen that were retained in the floor pens.
Challenge at 7 wk. Of the chickens remaining at 7 wk, five birds per pen were randomly selected and retained for a challenge study. The selected chickens in two of the four pens per treatment were each challenged by gavage (1 mL) with a mixture of 60,000 oocysts of E. acervulina, 20,000 oocysts of E. tenella, and 20,000 oocysts of E. maxima. Chickens in the other two pens per treatment remained unchallenged controls. For this challenge, chickens remained in their floor pens, and all were fed unmedicated grower ration. At 6 d PC, birds were weighed and killed, lesions were scored, and weight gains and feed conversions determined.
Statistical Analyses
Data were analyzed using the General Linear models procedure of SAS ® (SAS Institute, 1990), and significant 
RESULTS
Growout
At 3 wk, end of the starter period, chicks in Treatment 1 had gained significantly more weight than birds in the other treatment groups (Table 1 ). All other treatments elicited no significant differences in mean weight gain. Feed conversions for chicks in Treatments 1 and 2 were also significantly lower than for chicks on other treatments.
As expected, lesions were observed in chickens from all treatments, arising from exposure to coccidia oocysts both in the oral vaccine or from the seeded litter. The lesion scores of the three intestinal areas examined were all low, and there were no significant differences among treatments in scores for each area of intestine (Table 2) . However, the mean total score for chickens from Treatment 5, (immunized and rbST-treated) was significantly higher than total scores for chickens from Treatments 3 and 4 that received only rbST or only live oocysts respectively (Table 2 ). There were no significant differences among treatments in mortality at 3 wk which ranged from 1 to 4%.
At 7 wk, the end of the grower period, there were no significant differences among the treatment groups with respect to weight gain and feed conversion (Table 1) . Lesion scores were not determined at this time period. The final mean BW of the medicated controls was the highest ( Table 1 ). Chickens that had been treated only with rbST had a mean final BW not significantly different from the medicated controls. The final mean BW of the other two treatment groups were significantly lower than that of the unmedicated controls (Table 1) .
Week 3 Challenge
At 6 d PC, challenge infection produced an approximate 15% decrease in weight gain across all treatments compared with birds remaining in the floor pens (Table 3) . Among the challenged birds, the mean gains of chicks on Treatment 3 or Treatment 2 were not significantly different from mean gain of Treatment 1 chickens (Table  3) . On the other hand, mean gains of chicks on Treatments 5 and 4 were significantly lower than those of Treatments 1 and 3. The mean feed conversion of challenged chicks in Treatment 5 was significantly higher than that of the challenged medicated controls (Treatment 1). Feed conversions of the other challenged treatments were intermediate.
Week 7 Challenge
There were no significant differences in mean weight gains between the challenged and unchallenged groups within each treatment. Additionally, there were no significant differences in gain among the unchallenged treatment groups (Table 5 ). However, among the challenged groups, there was a significant difference in mean gain observed between Treatment 1 and Treatment 2 chicks. Mean gains of the chicks on the other treatments were intermediate (Table 5 ). There were no significant differences among the treatment groups with respect to feed conversion (Table 5) .
Low lesion scores attributable to E. acervulina were measured in all unchallenged treatments except Treatment 5, and in all challenged treatments (Table 6) . A lesion attributable to E. maxima was found in one chicken in the challenged Treatment 1 group (Table 6) . No cecal lesions attributable to E. tenella were seen in any of the challenged or unchallenged treatment groups (Table 6) .
DISCUSSION
This experiment was set up to simulate conditions in a commercial broiler house where coccidia oocysts are present in the litter, and to determine whether, under these circumstances, rbST might serve as a nonspecific adjuvant in immunizing broiler chickens against coccidiosis.
Final BW is one of the production parameters important to the commercial grower. As might be expected, the final mean weight of the medicated controls (Treatment 1) was the highest. However, chickens that had been treated with rbST alone (Treatment 3) had a mean final weight that was 96% of and not significantly different from that of the medicated controls, but was significantly higher than that of the untreated chickens (Treatment 2) ( Table 1) . One interpretation of these results is that rbST treatment by itself was sufficient to stimulate development of significant protective immunity just from exposure of the chickens to the oocysts in the litter. On the other hand, chickens that had been immunized with live oocysts, either alone or in combination with rbST (Treatments 4 and 5), had final mean weights that did not differ statistically from those of the untreated chicks. The expectation was that Treatments 4 and 5 would result in performance that was at least better than the untreated chickens. One explanation for why they did not might be that the two treatments, in addition to the antigenic stimulation elicited by the oocysts in the litter, provided too much stimulation to the immune system, diverting metabolizable energy away from growth. Depressed weight gains and increased feed conversions for these two groups, particularly during the first 3 wk (Table 1) , are consistent with this hypothesis.
It has become increasingly clear that immune stimulation has the potential to adversely affect growth in chickens. (Klasing et al., 1987; Johnstone and Klasing, 1990; Klasing and Johnstone, 1991; Benson et al., 1993; Cook et al., 1993) . Chamblee et al. (1992) have reported that vaccination of day-old chicks for a number of common poultry diseases leads to reduced performance in the absence of overt disease symptoms. It follows that administration of fewer oocysts in the live vaccine or a lower dose of rbST might result in better final BW for chickens in Treatment 5.
Low lesion scores were observed at 3 wk in randomly selected chickens from all treatments, and there were no statistically significant differences in mean scores among the treatments in any of the areas of the intestine that were examined (Table 2 ). These results indicate that immunization was not yet complete. This conclusion was further enforced by the across-treatment 15% drop in weight gain and the relative decreased weight gains and increased feed conversions seen particularly in Treatments 4 and 5 (Table 3 ) upon challenge infection.
Interestingly, mean lesion scores for Treatment 5 were low (upper SI and ceca) compared to scores from other treatments ( Table 4 ), suggesting that this treatment was more successful in controlling specific infection than the others, but at the expense of weight gain.
By 7 wk, immunity to coccidiosis in chickens on all treatments except Treatment 2 appeared to be complete as evidenced by the lack of weight gain depression upon challenge (with even a higher challenge dose than at 3 wk) (Table 5 ), the lack of cecal and mid-SI lesions (Table  6) , and the very low lesion scores attributable to E. acervulina (not statistically different from 0). Lesion scores due to E. acervulina were slightly but significantly increased upon challenge of Treatment 5 chickens (Table  6) . Whether this was due to actual parasite invasion or to an inflammatory response remains unclear.
The data suggest that rbST may be potentially useful as a nonspecific adjuvant to stimulate immunity to coccidia in the presence of a live vaccine. However, more work is required to optimize the ratio of rbST and live oocysts in order to provide protective immunity without impairment to weight gain.
